Partnered with Welt to apply 'Distributed Clinical Trials (DCT)' to digital treatments for insomnia for the first time in Korea.

Partnered with Welt to apply 'Distributed Clinical Trials (DCT)' to digital treatments for insomnia for the first time in Korea.

JNPMEDI (CEO Kwun-ho Jeong), a medical data platform company, announced on the 19th that it will apply its own developed distributed clinical trials (DCT) solution "Maven DCT Suite" to the digital healthcare company Welt (CEO Sung-ji Kang)'s confirmation clinical trial for insomnia digital treatments.

After the pandemic, the 'Distributed Clinical Trials (DCT)' market was activated worldwide. Domestic market is also getting more interested in DCT.

The introduction of DCT, which has achieved digital transformation in the clinical trial process, is expected to reduce costs and time as well as increase accuracy.

JNPMEDI has partnered with Welt to open a new market for clinical trials in Korea. The first step is to start with a digital cure for insomnia.

In the future, we will continue to prove the value of digitalization utility in the clinical market by creating various DCT application cases.

JNPMEDI and Welt plan to apply their own developed distributed clinical trial (DCT) solution to confirmation clinical trials for digital treatments for insomnia.

While the digital transformation of clinical trials is emerging as an important paradigm around the world, cases of digital clinical trials based on domestic technology are drawing attention as they are applied to digital treatments for insomnia for the first time in Korea.

The Maven DCT Suite is a world-class clinical trial platform and is drawing attention as a new alternative to lead the next-generation clinical industry with high technology such as convenient data collection, high accuracy of hit rate analysis, optimized interface, and high reliability based on blockchain.

This digital treatment for insomnia, DCT, is with Yonsei University Sinchon Severance Hospital. The entire clinical process of installing an application-type digital treatment developed by Welt on a smartphone and being followed by researchers will be conducted through the Maven DCT Suite.

Clinical subjects will go through a screening process to select suitability after recruitment through SNS, and most processes such as electronic informed consents (eConsent) for electronic consent and clinical outcome assistance (eCOA) for collecting clinical data using mobile devices are conducted non-face-to-face-to-face.

Until now, demand for decentralized digitalization has been increasing in the clinical trial sector, but due to unresolved regulations and unexplored environments, there have been many restrictions on expanding the market, such as relying on expensive foreign solutions overseas even if DCT.

DCT is a non-face-to-face clinical trial process from recruitment to consent to participation, data collection, monitoring, and prescription, which has been noted as a key to the advancement of the clinical trial industry, as well as shortening clinical period, reducing costs, and increasing accuracy. With the advent of COVID-19, voices for the need for DCT have been raised as it has been suffering from clinical delays in the medical and health industries.

Regarding the background of choosing the clinical trial method as DCT, CEO Sung-ji Kang said, "Digital therapy devices are living treatments that patients directly enter data and clinicians monitor in real time. JNPMEDI's DCT solution will be used for product management even after approval, and it is expected to reduce local clinical costs and speed up trials when entering overseas.

"This case will serve as an opportunity to inform all clinical trial officials that DCT is effective, along with the fact that it can be applied in Korea," said Kwun-ho Jeong CEO of JNPMEDI. "As the desire for clinical trial change through digital technology is essential, we will continue to prove it through various DCT application cases."

Meanwhile, according to Mirae Asset Securities Research Center data, the DCT market is expected to grow more than 47.4% annually from $2.6 billion in 2022 to $12.6 billion in 2026, accounting for about 18.6% of the total clinical development market in the future.